Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 4, 2003
Issued Date -
N/A
app pub date -
Sep 29, 2000
filing date -
May 28, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56.sup.lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully